Literature DB >> 6198285

Production and characterization of monoclonal antibodies to tetanus toxin.

A J Sheppard, D Cussell, M Hughes.   

Abstract

Monoclonal antibodies against tetanus toxin were produced to obtain highly specific antisera. Ten hybridoma cell lines producing monoclonal antibodies were derived from the fusion of rat myeloma cells and spleen cells from rats immunized with tetanus toxoid. Eight produced monoclonal antibodies specific for determinants on toxin and toxoid, whereas two were specific only for determinants on the toxoid. The antibodies produced by hybridomas were characterized by determination of the class of light and heavy chain components, epitope specificity, toxin neutralization, and subunit specificity. All of the antibodies contained kappa light chain, eight contained the gamma 1 heavy chain, and the remaining two contained the gamma 2a heavy chain. Five distinct epitopes were indicated by competition assay of paired monoclonal antibodies, and 4 of the 10 monoclonal antibodies neutralized the in vivo activity of tetanus toxin. The four neutralizing monoclonal antibodies and one other were specific for the C fragment of the heavy chain of the toxin molecule.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198285      PMCID: PMC264358          DOI: 10.1128/iai.43.2.710-714.1984

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  SELECTION OF HYBRIDS FROM MATINGS OF FIBROBLASTS IN VITRO AND THEIR PRESUMED RECOMBINANTS.

Authors:  J W LITTLEFIELD
Journal:  Science       Date:  1964-08-14       Impact factor: 47.728

2.  Proceedings: Structure-function relationship of tetanus toxin: studies on "complementary" polypeptide fragments of the toxin.

Authors:  M Matsuda; T Hara; M Yoneda
Journal:  Jpn J Med Sci Biol       Date:  1975 Oct-Dec

3.  Binding of ganglioside by the chains of tetanus toxin.

Authors:  S van Heyningen
Journal:  FEBS Lett       Date:  1976-09-15       Impact factor: 4.124

4.  Studies on tetanus antitoxins. II. Demonstration of at least four antitoxins of different specificity in antitoxic sera.

Authors:  J Nagel; H Cohen
Journal:  J Immunol       Date:  1973-05       Impact factor: 5.422

5.  Isolation and purification of two antigenically active, "complimentary" polypeptide fragments of tetanus neurotoxin.

Authors:  M Matsuda; M Yoneda
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

6.  Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments.

Authors:  T B Helting; O Zwisler
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

7.  The immunopurification of tetanus toxoid.

Authors:  M Hughes; R O Thomson; P Knight; J Stephen
Journal:  J Appl Bacteriol       Date:  1974-12

8.  Immunization against neonatal tetanus in New Guinea. 3. The toxin-neutralization test and the response of guinea-pigs to the toxoids as used in the immunization schedules in New Guinea.

Authors:  M F Barile; M C Hardegree; M Pittman
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

9.  Immunoglobulin classes of human antitoxin after tetanus vaccination studied by immunofluorescence with agarose bound tetanus toxoid.

Authors:  R Hernandez; M Just; A Bürgin-Wolff
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1973-06

10.  Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers.

Authors:  W J Yount; M M Dorner; H G Kunkel; E A Kabat
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  13 in total

1.  Synthesis of tetanus toxin fragment C in insect cells by use of a baculovirus expression system.

Authors:  I G Charles; B C Rodgers; A J Makoff; S N Chatfield; D E Slater; N F Fairweather
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

2.  Monoclonal B-cell response to diphtheria toxoid: evidence for cross-reactive epitopes.

Authors:  B Autran; F Triebel; M Viguier; M Jolivet; P Falmagne; P Debre
Journal:  Immunology       Date:  1987-04       Impact factor: 7.397

3.  Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin.

Authors:  S F Little; S H Leppla; E Cora
Journal:  Infect Immun       Date:  1988-07       Impact factor: 3.441

4.  Enzymatic hydrolysis of tetanus toxin by intrinsic and extrinsic proteases. Characterization of the fragments by monoclonal antibodies.

Authors:  K Goretzki; E Habermann
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

5.  Antibodies against the light chain of tetanus toxin in human sera.

Authors:  C S Lin; W H Habig; M C Hardegree
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

6.  Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier.

Authors:  N F Fairweather; S N Chatfield; A J Makoff; R A Strugnell; J Bester; D J Maskell; G Dougan
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

7.  Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT-rich DNA.

Authors:  M A Romanos; A J Makoff; N F Fairweather; K M Beesley; D E Slater; F B Rayment; M M Payne; J J Clare
Journal:  Nucleic Acids Res       Date:  1991-04-11       Impact factor: 16.971

8.  Production and characterization of monoclonal antibodies against Clostridium perfringens type A enterotoxin.

Authors:  A P Wnek; R J Strouse; B A McClane
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

9.  Production and characterization of monoclonal antibodies to Clostridium perfringens enterotoxin.

Authors:  Y Horiguchi; T Uemura; Y Kamata; S Kozaki; G Sakaguchi
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

10.  Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule.

Authors:  W A Volk; B Bizzini; R M Snyder; E Bernhard; R R Wagner
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.